Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT versus DEXILANT SOLUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT versus DEXILANT SOLUTAB.
DEXILANT vs DEXILANT SOLUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
30 mg orally once daily for up to 8 weeks; for healing esophagitis, 60 mg orally once daily for up to 8 weeks; maintenance 30 mg orally once daily.
30 mg orally once daily for 4-8 weeks; for non-erosive GERD, 30 mg orally once daily for 4 weeks; for erosive esophagitis, 60 mg orally once daily for up to 8 weeks; for maintenance of healed EE and relief of heartburn, 30 mg orally once daily. Administer without regard to food; dissolve tablet in water.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours in healthy subjects, but due to prolonged gastric acid suppression via irreversible binding to proton pumps, duration of action exceeds 24 hours. Half-life is not directly correlated with pharmacodynamic effect.
Terminal elimination half-life is approximately 1-2 hours; however, the pharmacodynamic half-life (duration of acid suppression) is prolonged due to accumulation in parietal cell canaliculi.
Renal (approximately 50% as inactive metabolites) and fecal (approximately 50% as inactive metabolites).
Renal (approx. 53% as metabolites, <2% as unchanged drug), biliary/fecal (approx. 47%).
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor